Aims The Glycine389 variant of the beta-1 adrenergic receptor generates markedly less cAMP when stimulated in vitro than the more prevalent Arginine389 variant and may confer protection against coronary events similar to that observed with beta-blockers. The aim of this study was to ascertain whether this Glycine389 variant protects against coronary events.
Introduction
The beta-1 adrenergic receptor ( 1AR) is the predominant adrenergic receptor expressed on the heart, mediating the physiological effect (cardiac ionotropy and chronotropy) of noradrenaline release from sympathetic nerve terminals. The clinical importance of the function of this receptor is demonstrated by the therapeutic response to beta-blockade. Through inhibition of this receptor, beta-blockers have favourably influenced the natural history of cardiovascular disease, particularly coronary artery disease [1] .
The 1AR is a member of the adrenergic family of membrane-bound G protein coupled receptors. The GTP binding protein (G protein) interacts with the intracellular domains of the receptor, and following agonist binding, dissociates from the receptor and stimulates adenylate cyclase to generate cAMP. This activates various intracellular processes including the influx of calcium through L-type calcium channels resulting in cardiac ionotropy and chronotropy [2] . The Arg389Gly polymorphism results in the substitution of the amino acid, arginine by glycine, at a critical site for G protein coupling (Fig. 1) . Recently in a biochemical model it has been demonstrated that the cAMP signal produced by the more common arginine form (Arg389), is threefold that of the Glycine (Gly389) [3] . Arg389 therefore could be termed the more active form of the receptor. Alter-natively it could be argued that individuals possessing the less common Gly389 are naturally 'beta-blocked'. This genetic polymorphism therefore could account for some of the inter-individual variability observed in the natural history of cardiovascular disease and might also influence an individual's susceptibility to disease. Importantly, evidence from clinical studies and experimental work indicate that such a functional variant would be predicted to influence susceptibility to coronary events.
The sympathetic nervous system has been unequivocally linked to the development and progression of cardiovascular disease [4] . Resting heart rate and a type A personality are both independent predictors of risk [5, 6] . The increased heart rate, cardiac contractility and renin production resulting from 1AR stimulation promotes arterial flow aberrations and pressure related wall stress, favouring endothelial injury and plaque rupture [7, 8] .
The favourable effect of beta-blockers on coronary events also provides a rationale for a protective effect of the 'less active' Gly389 receptor. The circadian pattern of myocardial infarction, linked to an increase in sympathetic activity in the early hours, is abolished by non-selective beta-blockade [9, 10] . In the secondary prevention of myocardial infarction, 1-selective blockers significantly reduce mortality and the incidence of re-infarction [1] . In the primary prevention setting there is also evidence to support a protective role of beta-blockade [1, 11] . A genetic predisposition to coronary disease is well established, and in view of the adverse effects of catecholamines and the benefit from beta-blockade, we hypothesized that the Arg389Gly polymorphism of the human 1AR may be a contributing factor.
Methods

Study design
In the West of Scotland Coronary Prevention study, 6595 men who had LDL cholesterol levels between 174 and 232 mg per decilitre, but with no history of myocardial infarction, were randomly assigned to receive 40 mg of pravastatin or placebo daily [12] . All subjects provided written informed consent. The study was approved by the ethics committee of the University of Glasgow, and all participating health boards. A risk reduction of 31% in the incidence of the primary end-point, a composite of non-fatal myocardial infarction and death from coronary artery disease, was seen in those on pravastatin treatment. Risk reductions of the same magnitude were seen for revascularization procedures (coronary artery bypass and percutaneous transluminal coronary angioplasty). Since the same underlying antithrombotic process is believed to give rise to myocardial infarction or death from cardiac causes as a first event, in the present case control study we used an expanded end-point comprising the primary end-point plus revascularization as a first event. Five hundred and eighty 'cases' (503 who had a myocardial infarction or died from cardiac causes as a first event, and 77 who underwent revascularization as a first event) were matched with two controls (also drawn from the cohort of 6595 men) for a total of 1160 controls. They were matched on the basis of age (using 2-year age categories) and smoking status, with subjects categorized as either non-smokers (those who had never smoked or who had stopped smoking) or current smokers. At randomization, 6% of patients with an event and 2·9% of controls were taking aspirin. Resting heart rate and blood pressure were measured at baseline. Individuals taking rate-modifying therapy or antihypertensive agents were excluded from the heart rate and blood pressure analysis respectively.
Determination of Arg389Gly genotype
Each individual was genotyped for the Arg389Gly polymorphism using an assay previously described [13] . Briefly, a 530bp fragment containing the polymorphic site was amplified by PCR using the following oligonucleotides:
Forward primer: CGCTCTGCTGGCTGCCCTTCT TCC Reverse primer: TGGGCTTCGAGTTCACCTGCT ATC The Arg389 allele PCR product contains a unique site for restriction by Bcg1 restriction endonuclease, thus cleavage of the 530 bp fragment into fragments of 342 and 154 bp confirms the presence of this allele. The resultant DNA fragments are separated by electrophoresis on a 2% agarose gel containing ethidium bromide and visualized under UV light (Fig. 2) .
Statistical analysis
A Chi-square test was used to study the differences in prevalence of the three genotypes in the event and control groups and conditional logistic regression was used to calculate odds ratios with 95% confidence intervals for each genotype. A similar analysis was conducted on the subgroup that smoked. An association of this polymorphism with baseline haemodynamic variables (resting heart rate and blood pressure) and other coronary risk factors was sought using t-tests.
Results
The baseline characteristics of the event and control groups in the current analysis and the subjects in the original study group are shown in Table 1 . As compared with the entire original study cohort the patients who had a coronary event were older and more likely to be smokers and had higher blood pressure and LDL cholesterol levels and lower HDL cholesterol levels, than those without an event. A history of diabetes, hypertension, chest pain and nitrate use were all predictors of coronary events in the trial itself and the proportions of subjects with these characteristics differed between patients and controls in the current study.
One thousand five hundred and fifty-four individuals from the cohort of 1740 were successfully genotyped. DNA extraction failed in 124 and the assay failed to yield a definitive result in 62. The allelic prevalence, arginine 0·73, glycine 0·27, was consistent with previous population studies [3, 13] . The overall prevalence of the three genotypes in the entire cohort were ArgArg (homozygous wild-type) 53·5%, ArgGly (heterozygote) 39·6%, GlyGly (homozygous mutant) 6·9% ( Table 2) . The genotype frequencies were in Hardy-Weinberg equilibrium (P=0·64).
There was no significant difference in distribution of alleles/genotypes between the event and control groups, thereby offering no support to the theoretical association of this polymorphism with coronary events (Table 2 ). Using the ArgArg genotype as the reference, the odds ratio for the ArgGly genotype was 1·1 (95% CI, 0·88-1·38) and for the GlyGly genotype it was 1·05 (95% CI, 0·68-1·62) ( Table 2) .
Fifty-four percent of the cohort smoked and similarly in this smoking subgroup there was no significant difference in the distribution of genotypes between the event and control groups. In smokers, using the ArgArg genotype as the reference, the odds ratios for the ArgGly genotype was 1·2 (95% CI, 0·90-1·66) and for the GlyGly genotype 0·9 (95% CI, 0·51-1·72).
No association was found with the baseline haemodynamic variables of resting heart rate, systolic or diastolic blood pressure (Table 3) . No association was found between this polymorphism and other coronary risk factors: body mass index, serum lipids and fibrinogen levels (data not shown).
Discussion
Based on 5 years of follow-up, we have observed that the distribution of genotypes of the Arg389Gly polymorphism was identical in individuals who either had a coronary event (fatal/non-fatal myocardial infarction, revascularization) or were free from an event. Furthermore, the distribution of genotypes as a whole was the same as has been previously reported for populations not selected on the basis of a potential cardiovascular risk [3, 13] . There appears, therefore, to be no association of this polymorphism with coronary events.
Given the in vitro functional effect of the Arg389Gly polymorphism and the size of our cohort we sought an association with baseline heart rate and blood pressure. We found no evidence of an intermediate effect manifested as either heart rate or blood pressure differences related to genotype. However, this haemodynamic analysis should be regarded with some caution. Individuals on antihypertensive agents (15%) were excluded from the blood pressure analysis to eliminate the haemodynamic effect of drug treatment. Therefore this analysis was performed on a pre-selected normotensive population and cannot exclude an association of this polymorphism with hypertension. Comparison of baseline blood pressure between genotypes, without exclusion of those individuals on antihypertensive therapy, similarly did not identify an association between blood pressure and these 1AR variants. The absence of a physiological effect in vivo is further supported by data from three small recent studies [14] [15] [16] . Given the large number of smokers in our cohort (53%) we thought it worthwhile to study the distribution of genotypes in this subgroup. Cardiac noradrenaline spillover is higher in smokers and nicotine promotes noradrenaline release from sympathetic nerve terminals [17] . Furthermore, in the MAPHY study, smokers alone gained a significantly greater coronary mortality benefit from 1-selective blockade compared to alternative therapies (thiazides) [18] . Despite this evidence, our analysis indicates identical distribution of genotypes in smokers with or without coronary events.
The marked difference in biochemical function in vitro of this important receptor as a result of a single amino acid substitution, Arg389Gly, provides a rationale for a potential influence of this polymorphism on coronary event risk. Therefore our observation that such a difference does not translate to a measurable physiological effect in man, is of particular interest. However, it should be emphasized that the evidence for functional differences was derived from a recombinant system using cultured hamster fibroblasts [3] . Furthermore, recent experimental work suggests that Arg389 receptors desensitize more readily than the Gly389 variant, thus potentially offsetting differences in vivo [19] . Finally, cAMP levels in the cell are dependent on many processes, particularly breakdown by phosphodiesterase activity.
In a complex pathogenic process like coronary thrombosis, the interaction of multiple polymorphic loci is more likely to determine phenotype than a single polymorphism in isolation. In addition to the 1AR, the sympathetic nervous system embraces other adrenergic receptors, which modulate inflammation, platelet aggregation and vascular smooth muscle cell proliferation [20] [21] [22] . These too display polymorphisms [23, 24] . The Ser49Gly polymorphism located within the amino terminal of the 1AR itself may play a part by modifying 1 receptor expression [13] . Furthermore, potential variants of the numerous proteins downstream of the 1AR need to be considered. The absence of a clinical effect observed in our coronary event cohort, however, does not exclude the existence of a more subtle effect potentially identifiable in other disease populations. The WOSCOPS study was a primary prevention study but was located in the West of Scotland, an area with one of the highest coronary mortality rates in the U.K. (>230 per 100 000) [25] . A study in a post myocardial population, where the effect of beta-blockade has been more convincingly demonstrated, is necessary to further determine the importance of this Glycine variant. In heart failure, a condition in which sympathetic activity is greatly enhanced, there are other pathogenic processes mediated by the 1AR in addition to its pro-atherogenic effect. Stimulation of this important receptor increases oxygen demand, wall tension, myocyte apoptosis and necrosis [26] . Data from a recent association study suggest that the Gly49 variant of the 1AR is associated with improvement in long-term survival in patients with heart failure [27] . Yet, following correction for other relevant variables, the survival difference was of borderline significance. No association was identified however by Tesson et al. , between the Arg389Gly polymorphism and idiopathic dilated cardiomyopathy [28] .
In conclusion, an odds ratio for the GlyGly genotype of 1·05 suggests that there is no major effect of this 1AR 389Gly variant on coronary events. Six thousand five hundred and ninety-five individuals were followed for 5 years in order to observe these events. Environmental factors such as smoking increase the risk of early coronary events 2-4-fold. In the present study, the upper confidence limit for the GlyGly genotype was 1·62. However, genotypic risk ratios seen in conditions such as familial hypercholesterolaemia range from 10 000 in those aged less than 30 years old, to 44 in those aged over 66 years. Furthermore, the many published studies of genetic polymorphisms and myocardial infarction indicate that a genetic risk ratio of less than 1·5 is rarely identified as statistically significant. The lower 95% confidence limit of 0·68 does not completely exclude an effect of the magnitude observed with beta-blockers (25% risk reduction). However to exclude this, a similar 5-year follow-up of over 20 000 individuals would be Mean blood pressure=BP. Mean heart rate=HR. Numbers in brackets represent standard deviation. Individuals on rate modifying therapy (n=201) were excluded from heart rate analysis. Individuals on antihypertensive therapy (n=235) were excluded from BP analysis.
required. Consequently, we consider that we have ruled out a major influential role for this 1AR Arg389Gly polymorphism on coronary events, within the practical constraints of this type of research.
